Internal restructuring
Sydsverige; Skåne län;
Location of affected unit(s)
Wholesale Trade, Except Of Motor Vehicles And Motorcycles
Wholesale Of Household Goods
46.46 - Wholesale of pharmaceutical goods

360 jobs
Number of planned job losses
Job loss
Announcement Date
10 October 2018
Employment effect (start)
1 January 2019
Foreseen end date
31 December 2022


The American pharmaceutical company Baxter is closing its production line in Lund (Sweden), resulting in a total of 360 employee dismissals. This is part of a large-scale restructuring within the Baxter group. Employment reductions will come into effect during 2019 and go on through to 2022.

Baxter has approximately 540 employees at its Lund site, meaning 2/3 of total employees will be dismissed. This includes all 250 workers on the production line, 40 workers in research and development and 70 workers in support. As a result of the restructuring, Baxter's site in Italy will be the basis for the company's European production. 

A company spokesperson commented that the research and development division as well as some of the support functions will stay in Lund and that new competencies will be needed there during the coming years. This means that, even though production will no longer take place in Lund, other key operations will stay at the site and offer employment in other sectors of the company. 



Eurofound (2018), Baxter, Internal restructuring in Sweden, factsheet number 95627, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/95627.